A5008572001- Veterinary Pharmacology and Anesthesia
- Anesthesia and Pain Management
- Inflammatory mediators and NSAID effects
- Neurotransmitter Receptor Influence on Behavior
- Anesthesia and Sedative Agents
- EEG and Brain-Computer Interfaces
- Psychedelics and Drug Studies
- Pain Mechanisms and Treatments
- Sleep and Wakefulness Research
- Allergic Rhinitis and Sensitization
- Neural dynamics and brain function
- Treatment of Major Depression
- Electroconvulsive Therapy Studies
- Epilepsy research and treatment
- Sleep and related disorders
- Cholinesterase and Neurodegenerative Diseases
- Pharmacogenetics and Drug Metabolism
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Opioid Use Disorder Treatment
- Trypanosoma species research and implications
- Forensic Toxicology and Drug Analysis
- Cystic Fibrosis Research Advances
- Autoimmune and Inflammatory Disorders Research
- Cerebral Venous Sinus Thrombosis
- Alzheimer's disease research and treatments
Esteve (Spain)
2017-2024
Esteve Química (Spain)
2019-2022
Hospital de Sant Pau
1997-2007
Universitat Autònoma de Barcelona
2001-2005
Vall d'Hebron Institut de Recerca
2005
Centre for Research in Anthropology
1999
Hospital de l'Esperança
1999
Puigvert Foundation
1999
The effects of the South American psychotropic beverage ayahuasca on subjective and cardiovascular variables urine monoamine metabolite excretion were evaluated, together with drug9s pharmacokinetic profile, in a double-blind placebo-controlled clinical trial. This pharmacologically complex tea, commonly obtained from <i>Banisteriopsis caapi</i> <i>Psychotria viridis</i>, combines <i>N,N</i>-dimethyltryptamine (DMT), an orally labile psychedelic agent showing 5-hydroxytryptamine<sub>2A</sub>...
Objective This narrative review aims to provide a clinical perspective on the potential role of co-crystal tramadol–celecoxib (CTC) in management acute moderate-to-severe pain by synthesizing available preclinical and data, with emphasis phase 3 trials.
Co-crystal of tramadol-celecoxib (CTC) is the first analgesic co-crystal for acute pain. This completed phase 3 multicenter, double-blind trial assessed efficacy and safety/tolerability CTC in comparison with that tramadol setting moderate-to-severe pain up to 72 h after elective third molar extraction requiring bone removal. Adults (n = 726) were assigned randomly five groups (2:2:2:2:1): orally administered twice-daily 100 mg (44 rac-tramadol hydrochloride/56 celecoxib; n 164), 150 (66/84...
Aims Ayahuasca is a traditional South American psychoactive beverage used in Amazonian shamanism, and the religious ceremonies of Brazilian‐based syncretic groups with followers US several European countries. This tea contains measurable amounts psychotropic indole N , ‐dimethyltryptamine (DMT), β‐carboline alkaloids MAO‐inhibiting properties. In previous report we described profile stimulant psychedelic effects for ayahuasca as measured by subjective self‐assessment instruments. present...
Noradrenergic neurotransmission has been associated with the modulation of higher cognitive functions mediated by prefrontal cortex. In present study, impact noradrenergic stimulation on human action-monitoring system, as indexed event-related brain potentials, was examined. After administration a placebo or selective α 2 -adrenoceptor antagonist yohimbine, which stimulates firing in locus ceruleus and noradrenaline release, electroencephalograpic recordings were obtained from healthy...
PurposeCelecoxib-tramadol co-crystal (CTC) is a first-in-class of celecoxib and racemic tramadol. This Phase 1 bioavailability study compared single-dose pharmacokinetic (PK) parameters CTC with those the individual reference products from United States, immediate-release tramadol, taken alone simultaneously to determine their systemic exposure.MethodsThis was single-center, randomized, single-dose, open-label, 4-period, 4-sequence, crossover conducted in healthy subjects between October...
Abstract Background We report the efficacy and safety of E‐52862—a selective, sigma‐1 receptor antagonist—from phase 2, randomized, proof‐of‐concept studies in patients with moderate‐to‐severe, neuropathic, chronic postsurgical pain (CPSP) painful diabetic neuropathy (PDN). Methods Adult (CPSP [ N = 116]; PDN 163]) were randomized at a 1:1 ratio to 4 weeks treatment E‐52862 n 55]; 85]) or placebo 61]; 78]) orally once daily. Pain intensity scores measured using numerical rating scale from 0...
Mucopolysaccharidosis type III is a progressive, neurodegenerative lysosomal storage disorder for which there currently no effective therapy. Though numerous potential therapies are in development, several challenges to conducting clinical research this area. We seek make recommendations on the approach MPS III, including selection of outcome measures and trial endpoints, order improve quality impact An international workshop involving academic researchers, experts industry groups was held...
Abstract Background Celecoxib‐tramadol co‐crystal (CTC) is a first‐in‐class analgesic of celecoxib and racemic tramadol with an improved pharmacologic profile, conferred by the structure, compared its active constituents administered alone/concomitantly. Aim We evaluated CTC in moderate‐to‐severe acute postoperative pain. Materials Methods This randomized, double‐blind, factorial, active‐ placebo‐controlled phase 3 trial (NCT03108482) was conducted at 6 US clinical research centers. Adults...
<i>Aims:</i> To assess peripheral anti-H<sub>1</sub> and central nervous system (CNS) activity of single increasing doses rupatidine fumarate (RU), a new antihistamine/platelet-activating factor antagonist compound, in comparison with hydroxyzine placebo. <i>Methods:</i> Eighteen healthy young subjects both sexes took part crossover, randomised, double-blind, placebo-controlled study. Treatments tested were: RU 10, 20, 40 80 mg 25 mg, as positive standard....
STARDOM2 is a randomized, double-blind, phase 3 trial evaluating the efficacy and safety of co-crystal tramadol-celecoxib (CTC)-a first-in-class analgesic comprising racemic tramadol hydrochloride celecoxib in supramolecular network that modifies their pharmacokinetic properties-for management acute postoperative pain (NCT03062644; EudraCT:2016-000593-38).Patients with moderate-to-severe following abdominal hysterectomy were randomized 2:2:2:2:2:1 to oral CTC 100 mg (rac-tramadol 44...
Abstract Background In the randomized, phase 3, SUSA‐301 trial, celecoxib‐tramadol co‐crystal (CTC) provided significantly greater analgesia compared with celecoxib, tramadol, or placebo in adults acute, moderate‐to‐severe, postoperative pain. This post hoc, secondary analysis further evaluated use of rescue medication and incidence treatment‐emergent adverse events (TEAEs). Methods Patients ( N = 637) were randomized 2:2:2:1 to receive oral CTC 200 mg twice daily (BID; n 184), tramadol 50...
<i>Aims:</i> To evaluate the potential interaction of 20 mg paroxetine and 1 alprazolam (early morning once-daily administration) on polysomnographic (PSG) sleep subjective awakening quality, both after a single intake reaching steady-state concentration. <i>Methods:</i> Twenty-two (11 for PSG) healthy young volunteers sexes with no history disturbances (Pittsburgh Sleep Quality Index <5) participated in double-blind, double-dummy, placebo-controlled,...
Objective To characterize the pharmacokinetic profile of somatostatin analog lanreotide in patients with severe chronic renal insufficiency. Methods Lanreotide was administered by intravenous bolus (7 ¼g/kg) to 12 insufficiency and healthy subjects. serum levels were determined a radioimmunoassay procedure from time 0 until 24 hours after administration. The main parameters estimated noncompartmental treatment data. Results total clearance found be significantly lower than subjects (mean ±...
This investigation aimed to provide evidence on the lack of pharmacokinetic interaction paroxetine (20 mg/d) and alprazolam (1 in combined therapy. In addition, central effects both drugs when administered alone combination were assessed rule out any relevant synergistic depressant effect. Twenty-five healthy young adult volunteers participated a double-blind, double-dummy, placebo-controlled, repeated dose (15 days), 4-period crossover study. Each subject received each 4 treatment sequences...
Background: Rivastigmine, a reversible AChEI for symptomatic treatment of mild to moderately severe Alzheimer’s dementia is administered in once daily transdermal patches enabling an easier and continuous drug delivery. A novel multi-day (twice week) patch formulation with greater convenience patients’ therapeutic management, was developed. Objective: To assess the bioequivalence under SS conditions multiple-day rivastigmine (Test Product, RID-TDS) comparison Exelon® (Reference Product),...
Electroencephalographic artifacts associated with eye movements are a potential source of error in the EEG analysis when its interpretation is performed for evaluating influence drugs and diagnosis neurological disorders. In this study, new automatic method artifact filtering based on independent component (ICA) proposed. Automatic identification frequency domain scalp topography aspects components. A comparative study between ICA 'gold standard' linear regression performed. The latter does...
<i>Objective:</i> The aim of this double-blind, randomized, crossover, placebo-controlled clinical trial was to compare the inhibition histamine-induced skin reaction induced by ebastine 20 mg with respect that fexofenadine 120 or placebo. <i>Methods:</i> Eighteen volunteers (10 males, 8 females) received three treatments once daily for 5 days, a mean 7-day washout period between treatments. Intradermal tests, using 0.05 ml from solution containing 100 µg/ml...
The time course of the pupillary light reflex (PLR) is determined by successive activation parasympathetic and sympathetic innervations iris, latency amplitude reflecting activity recovery showing mainly activity.To determine effects tobacco cigarette smoking on PLR in smokers after an abstinence period at least 12 h.Ten (mean 15.7 cigarettes/day) 10 non-smokers participated a randomised, non-intervention controlled, cross-over study that included parallel control group. Smokers underwent...
New acute pain medications are needed that provide effective analgesia while minimizing side effects and opioid exposure. Clinical trials of co-crystal tramadol-celecoxib (CTC) have demonstrated an improved benefit/risk profile versus tramadol or celecoxib alone. We pooled data from two phase 3 clinical to evaluate the efficacy CTC 200 mg twice daily (BID) in moderate-to-severe pain. Efficacy were STARDOM1 [acute following oral surgery (NCT02982161)] ESTEVE-SUSA-301 bunionectomy...